arrow
J

Joseph R. Marszalek

the university of texas m d anderson cancer center
H指数:44
被引数:9,855

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen

CDK2抑制增强了CDK4/6抑制剂在综合乳腺癌PDX模型筛选中的抗肿瘤活性

2025-12-030
OAAI
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

纳武利尤单抗联合伊匹木单抗诱导肾髓质癌发生超进展:一项II期试验结果及临床前证据

2025-11-250
OAAI
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
MABS
IF7.3
2024-12-090
OAAI
KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild-type amplifications
2024-10-010
PRE
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

共靶向SOS1通过解决内在和获得性耐药增强KRASG12C抑制剂的抗肿瘤作用

2024-08-051
OA
KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications
2024-03-220
PRE
KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models
2024-03-220
PRE
Chromosome 3 copy number loss alone drives tumor evolution to aggressive disease in uveal melanoma
2024-03-220
PRE
Development of advanced preclinical modeling for a comprehensive characterization of cardiac angiosarcoma biology
2024-03-220
PRE
BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRAS G12V-driven preclinical models
2023-12-010
PRE
BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in preclinical models and validates wild-type amplified KRAS as a therapeutic target
2023-12-010
PRE
Deploying spatial transcriptomics to inform intratumoral heterogeneity in late-stage uveal melanoma leveraging advanced preclinical modeling and clinical samples
2023-04-040
PRE
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

晚期实体瘤和急性髓性白血病中氧化磷酸化的复合物I抑制剂: I期试验

2023-01-19120
OA